United Therapeutics (UTHR) Shares Outstanding (Diluted Average) (2009 - 2026)

United Therapeutics has disclosed Shares Outstanding (Diluted Average) across 12 years of filings, most recently posting $47.2 million for Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $47.2 million, down 2.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.2 million (down 2.88% YoY), and the FY2025 annual result was $47.9 million, down 1.24% from the prior year.
• Shares Outstanding (Diluted Average) came in at $47.2 million for Q1 2026 at United Therapeutics, down from $47.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $49.7 million in Q4 2023 to a low of $47.2 million in Q1 2026.
• The 5-year median for Shares Outstanding (Diluted Average) is $48.5 million (2022), against an average of $48.6 million.
• Across the five-year window, Shares Outstanding (Diluted Average) advanced 3.98% in 2023 and dropped 2.88% in 2026, its largest moves.
• United Therapeutics' Shares Outstanding (Diluted Average) stood at $48.5 million in 2022, then climbed by 2.47% to $49.7 million in 2023, then slipped by 2.41% to $48.5 million in 2024, then fell by 1.24% to $47.9 million in 2025, then slipped by 1.46% to $47.2 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $47.2 million (Q1 2026), $47.9 million (Q4 2025), and $48.1 million (Q3 2025), per Business Quant data.